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Liu et al. show that CMPF is significantly
elevated in both prediabetes and type 2
diabetes. Rapid elevation in CMPF may
represent the tipping point in beta cell
function, playing a causal role in the
conversion from prediabetes to type 2
diabetes.
Cell Reports
ArticleRapid Elevation in CMPFMay Act As
a Tipping Point in Diabetes Development
Ying Liu,1,4 Kacey J. Prentice,1,4 Judith A. Eversley,1 Cheng Hu,3 Battsetseg Batchuluun,1 Katherine Leavey,2
Jakob B. Hansen,1 David W. Wei,1 Brian Cox,2 Feihan F. Dai,1 Weiping Jia,3,* and Michael B. Wheeler1,*
1Department of Physiology, University of Toronto, 1 King’s College Circle, Medical Sciences Building, Room 3352, Toronto, ON M5S
1A8, Canada
2Department of Physiology, University of Toronto, 1 King’s College Circle, Medical Sciences Building, Room 3360, Toronto, ON M5S
1A8, Canada
3Department of Endocrinology and Metabolism, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China
4Co-first author
*Correspondence: wpjia@sjtu.edu.cn (W.J.), michael.wheeler@utoronto.ca (M.B.W.)
http://dx.doi.org/10.1016/j.celrep.2016.02.079
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARY
Prediabetes, a state of mild glucose intolerance, can
persist for years before a sudden decline in beta cell
function and rapid deterioration to overt diabetes.
The mechanism underlying this tipping point of beta
cell dysfunction remains unknown. Here, the furan
fatty acid metabolite CMPF was evaluated in a pro-
spective cohort. Thosewhodevelopedovert diabetes
hada significant increase inCMPFover time,whereas
prediabetics maintained chronically elevated levels,
even up to 5 years before diagnosis. To evaluate the
effect of increasing CMPF on diabetes progression,
we used obese, insulin-resistant models of prediabe-
tes. CMPF accelerated diabetes development by
inducing metabolic remodeling, resulting in preferen-
tial utilization of fatty acids over glucose. This was
associated with diminished glucose-stimulated insu-
lin secretion, increased ROS formation, and accumu-
lation of proinsulin, all characteristics of human dia-
betes. Thus, an increase in CMPF may represent the
tippingpoint in diabetes developmentby accelerating
beta cell dysfunction.
INTRODUCTION
Type 2 diabetes (T2D) is a progressive disease characterized by
a significant decline in beta cell function, ultimately resulting in
insufficient insulin secretion to meet metabolic demands (Weir
and Bonner-Weir, 2004). In the early stages, increased demand
due to insulin resistance induces a state of beta cell compensa-
tion mediated by increases in beta cell mass and insulin secre-
tion to maintain euglycemia (Butler et al., 2003; Kahn, 2003;
Weyer et al., 1999). Chronically high insulin demand, in combina-
tion with environmental and genetic factors, is thought to
contribute to the initial stages of beta cell dysfunction, manifest-
ing as impaired fasting glucose (IFG) and impaired glucose-
tolerant (IGT) phenotypes, collectively termed prediabetes (Ab-
dul-Ghani and DeFronzo, 2009; Kahn, 2003). These individualsCellhave abnormalities in fasting blood glucose and/or amild impair-
ment during a glucose tolerance test (GTT; Bansal, 2015). Indi-
viduals with prediabetes are at a significantly elevated risk of
developing T2D if their beta cell function continues to decline,
with approximately 70% of prediabetic individuals eventually
developing T2D (Pan et al., 1997).
Individuals with prediabetes can maintain a state of glucose
intolerance for years before developing overt diabetes (Ferran-
nini et al., 2011; Tuomilehto et al., 2001). The deterioration
to T2D occurs at vastly different rates for different individuals,
though the conversion is directly correlated with a sudden
and drastic impairment in glucose-stimulated insulin secretion
(GSIS), independent of variables including BMI and insulin resis-
tance (Ferrannini et al., 2004; Weir and Bonner-Weir, 2004). The
mechanism underlying this tipping point of beta cell function,
mediating the conversion from prediabetes to T2D, remains
largely unknown. It has been suggested that chronic factors,
including glucolipotoxicity, inflammation, endoplasmic reticulum
(ER) stress, and/or oxidative stress may collectively exhaust the
beta cell compensatory capacity, reducing beta cell mass and
insulin secretion over time until compensation is no longer
feasible (Abdul-Ghani et al., 2006; Jonas et al., 2009; Poitout
and Robertson, 2008; Prentki and Nolan, 2006). However, this
chronic picture does not account for acute instances of beta
cell failure in response to insulin-resistant conditions. Gesta-
tional diabetes, a closely related condition to T2D that is also
characterized by beta cell failure in response to insulin resis-
tance, occurs acutely within weeks of insulin resistance onset
and is rapidly resolved following parturition (Buchanan and
Xiang, 2005). Therefore, we believe that underlying factors act
to accelerate beta cell dysfunction in the conversion frompredia-
betes to overt diabetes.
Recently, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid
(CMPF) was found to be significantly elevated in the plasma of
patients with gestational and T2D (Prentice et al., 2014). Further
studies in animal models revealed a potential causal role of
CMPF in diabetes development. However, the timingof the eleva-
tion inCMPF, and the role of CMPF in the deterioration of beta cell
function during the progression to diabetes, before diabetes
onset, has not yet been investigated. Here we performed a pro-
spective study examining CMPF levels in human participantsReports 14, 2889–2900, March 29, 2016 ª2016 The Authors 2889
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Figure 1. Plasma CMPF Is Elevated in Predi-
abetic and Diabetic Populations
(A) Plasma CMPF level was evaluated in human
fasting plasma samples collected in 2011–2012;
n = 50, 75, and 71 for normal, prediabetes, and
diabetes groups, respectively.
(B) Change of plasma CMPF level was evaluated in
plasma samples with both baseline (collected in
2007–2008) and follow-up (collected in 2011–
2012). n = 65 for NGT/ NGT and prediabetes/
prediabetes, which represent maintenance of a
non-diabetic state group; n = 57 for NGT/ dia-
betes and prediabetes/ diabetes, which repre-
sent a newly developed diabetes group.
Values are mean ± SEM, *p < 0.05, **p < 0.01,
***p < 0.001. See also Figure S1 and Tables S1–S4.during a 5 year follow-up period and studies in prediabetic (high-
fat diet, or HFD, and genetically predisposed) animal models to
determine whether rapid elevation in plasma CMPF levels partic-
ipates in the induction of beta cell failure and accelerates the
pathological progression of diabetes.
RESULTS
Evaluation of Plasma CMPF in a Prospective Population
Plasma samples from the selected cohort (Figure S1A) of individ-
uals at baseline (2007–2008; for clinical parameters, see Table
S1) and follow-up (2011–2012; for clinical parameters, see Table
S2) were evaluated for CMPF concentration. As anticipated, at
the follow-up visit, the newly diagnosed diabetic population
had significantly greater plasma CMPF concentration compared
to normal glucose-tolerant (NGT) controls (103.9 ± 11.38 mM in
diabetics versus 37.14 ± 6.350 mM in NGT controls, p < 0.001
ANOVA; Figure 1A). The levels of CMPF we detect in current dia-
betic patients are comparable to those in our previous report of
Caucasians (Prentice et al., 2014). Prediabetic individuals also
had a significantly greater CMPF compared to normal controls
at this time point (84.14 ± 10.90 mM versus 37.14 ± 6.350 mM,
p < 0.01 ANOVA; Figure 1A), suggesting that CMPF is associated
with both diabetes and prediabetes (Figure S1B).
Analysis of CMPF in plasma samples from the same popula-
tion at baseline, when all subjects were non-diabetic (Table
S1), revealed a trend between plasma CMPF and future diabetes
status. Individuals whowere prediabetic or diabetic at the follow-
up visit 4–5 years later tended to have increased levels of CMPF
compared to controls at baseline, with levels being significantly
elevated in future prediabetics (p = 0.025 future prediabetics
versus future NGT, p = 0.0718 future diabetics versus future
NGT, ANOVA; Table S3). We found that individuals with an in-
crease in plasma CMPF concentrations between baseline and
follow-up time points were at significantly higher risk of devel-
oping overt diabetes overall (p = 0.00198; Figure 1B; Table 1; Fig-
ure S1C). Those in the third and fourth quartiles of change, when
adjusted for age, sex, BMI, and estimated glomerular filtration
rate, had a significantly greater risk of developing diabetes
compared to those in the lower quartiles (Table 1). Therefore, a
large elevation in circulating CMPF concentration is associated
with increased risk of diabetes development.2890 Cell Reports 14, 2889–2900, March 29, 2016 ª2016 The AuthorElevated CMPF Impairs GSIS and Potentiates the
Development of Diabetes in Rodent Models
To examine the role of rapid elevation in plasma CMPF in the
context of pathological progression of diabetes, we used two
models of diabetes development: HFD feeding to produce
diet-induced obesity (DIO;Wang and Liao, 2012) and the genetic
Ob/Ob mouse model (Lindstro¨m, 2010). Both models mimic the
dyslipidemia and beta cell compensation for peripheral insulin
resistance that is characteristic of diabetes development in the
human population. These compensatory responses include in-
creases in beta cell mass and insulin secretion, and they occur
before the de-compensation and beta cell failure of overt dia-
betes (Lindstro¨m, 2010; Wang and Liao, 2012).
To establish our DIO diabetic model, we fed male CD1 mice a
HFD composed of 60% kcal from fat or a sucrose-matched con-
trol chow diet for 6 weeks. To examine the role of CMPF, we then
treated DIOmice with 6 mg/kg CMPF (Prentice et al., 2014) once
daily for an additional 2 weeks while maintaining the mice on the
HFD. DIO and chowmice injectedwith vehicle were used as con-
trols (Figure S1D). Eight-week-old male Ob/Ob mice were used
as a genetic model of diabetes development. These mice were
injected with 6 mg/kg CMPF once daily for 2 weeks, as in the
DIO model. Controls were treated with vehicle (Figure S1E).
There was no difference in body weight or food consumption
with CMPF treatment at the end of the treatment period in either
model (data not shown).
After 2 weeks of CMPF treatment, DIO mice treated with
CMPF (DIO-CMPF) exhibited even greater fasting blood glucose
concentrations than DIO-control mice, with no significant differ-
ence in fasting plasma insulin levels (Figures 2A and 2B). Unlike
the DIOmodel, CMPF had no additive effect on fasting hypergly-
cemia and hyperinsulinemia observed in the Ob/Ob-Control
mice, perhaps due to the existing severity of hyperglycemia in
Ob/Ob-controls (Figures 2C and 2D). In addition, DIO-CMPF
mice had an even greater impairment in glucose tolerance than
did DIO-controls, with a complete lack of GSIS during GTT (Fig-
ures 2E and 2G; Figure S2C). These results were mirrored in the
Ob/Ob mice treated with CMPF (Ob/Ob-CMPF). Despite signifi-
cant glucose intolerance in Ob/Ob-control mice, treatment with
CMPF acted to further impair glucose tolerance (Figure 2F),
which again correlated with a significant reduction in GSIS dur-
ing the GTT (Figure 2H; Figure S2D). Together, these datas
Table 1. Relation between the Change in CMPF Levels and the
Risk of Future Diabetes Development
Change in CMPF
Levels during 4–5 Year
Follow-up Period
Development of Diabetes Compared to
the Maintenance of a Non-diabetic State
Likelihood Ratio p Value
First quartile Baseline –
Second quartile 1.74 0.188
Third quartile 5.41 0.02a
Fourth quartile 7.35 0.00669a
Continuous 9.57 0.00198a
Values were treated as both continuous and categorical (split by quartile
of CMPF change, with the first quartile, the lowest observed change, em-
ployed as a baseline for comparison). Results are likelihood ratios for
diabetes development, obtained from conditional logistic regression
analysis. All models are adjusted for age, sex, BMI, and glomerular
filtration rate. n = 65 for NGT/ NGT and prediabetes/ prediabetes
(maintenance of a non-diabetic state). n = 57 for NGT/ diabetes and
prediabetes / diabetes (development of diabetes). All samples had
both baseline and outcome measurements for CMPF.
aValue is statistically significant at p < 0.05.suggest that CMPF acts to impair beta cell function to potentiate
diabetes development.
To verify that the observed worsening in glucose tolerance is
due to impaired beta cell function, we isolated islets from both
models and performed GSIS assays ex vivo. Consistent with
the observed impairment in GSIS during GTT, when we exam-
ined the glucose sensitivity of islets from individual mice, we
found that islets from DIO-CMPF and Ob/Ob-CMPF mice had
significantly reduced amplification in insulin secretion when
stimulated with high glucose concentrations as compared to
controls (Figures 2I and 2J; Figures S2A and S2B). The observed
defect in GSISwas not associated with a reduction in total insulin
content (Figures 2K and 2L) or differences in total insulin-positive
area, as determined in whole pancreatic sections (Figures 2M
and 2N), in either model, suggesting an alternate source of
beta cell dysfunction, such as defective glucose utilization.
CMPF Treatment Impairs Glucose Metabolism by
Metabolic Remodeling
The effect of CMPF on glucose metabolism was first assessed
by measuring changes in mitochondrial membrane potential
(MMP) in response to the acute addition of glucose. Islets from
both chow and DIO-control mice exhibited a robust hyperpolar-
ization of the MMP upon addition of 20 mM glucose (Figure 3A).
Islets fromDIO-CMPFmice, however, had a significantly blunted
response (Figure 3A), corresponding to the observed impairment
in GSIS. Remarkably, when the same assay was performed with
the acute addition of 400 mM palmitic acid, the DIO-CMPF
islets exhibited a greater hyperpolarization of the MMP than
did either control (Figure 3B). This was also observed in islets
from the Ob/Ob-CMPF mice compared to Ob/Ob-controls (Fig-
ures 3C and 3D). To further validate the changes in MMP in line
with downstream substrate oxidation, we measured the oxygen
consumption rate (OCR) in response to acute addition of glucose
or palmitic acid by Seahorse-based metabolic flux analyses.
Consistent with the observations in MMP, islets from DIO-CellCMPF mice exhibited significantly reduced glucose oxidation,
and correspondingly significantly enhanced fatty acid oxidation,
compared to DIO-controls (Figures 3E and 3F). To confirm that
this effect of enhanced fatty acid utilization was not specific to
murine islets, we treated human islets with vehicle, 400 mM
palmitate, or 200 mMCMPF for 24 hr and evaluated their capacity
for glucose oxidation. Pre-treatment with palmitate had no effect
on glucose response compared to vehicle control; however, hu-
man islets pre-treated with CMPF had a significantly blunted
response to the addition of glucose, consistent with the murine
models (Figure 3G). In addition, when fatty acid oxidation was
evaluated, we again observed a significantly enhanced response
from CMPF pre-treated islets compared to both control and pal-
mitic acid pre-treated islets (Figure 3H). In all assays, there was
no effect on mitochondrial oxidative capacity with CMPF treat-
ment, as indicated by identical elevations in the OCR after
carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP)
stimulation between control and CMPF pre-treated human islets
(Figures 3G and 3H), as well as no difference in expression of
genes regulatingmitochondrial oxidative capacity (see Figure 6C
later). Overall, we have determined that CMPF induces a state of
enhanced fatty acid utilization in islets, which reduces glucose
metabolism, resulting in impaired GSIS.
CMPF Treatment Reduces Glycolysis and Increases
Advanced Glycation End-Products and Oxidative Stress
The effect on fatty acid utilization prompted us to further examine
glucose utilization in islets fromCMPF-treatedmice. We first eval-
uated the capacity for CMPF-treated islets to uptake glucose.
CMPF treatment was associated with a significant increase in
glucose uptake (Figure 4B), despite no changes in the expression
of glucose transporter 2 (Glut2) at either the mRNA or the protein
level (Figures S2E and S2F). In addition, we did not observe
changes in expression of the rate-limiting enzyme in glycolysis,
glucokinase (Gck), suggesting that CMPF likely does not alter the
ability of cells to generate glucose-6-phosphate. CMPF treatment
was associatedwith a significant reduction in glycolysis, as evalu-
ated by the extracellular acidification rate (ECAR) in response to
the addition of glucose using Seahorse (Figure 4A). Furthermore,
the activity of pyruvate dehydrogenase (PDH) was also signifi-
cantly reduced with CMPF treatment (Figure 4C). Thus, treatment
with CMPF enhances glucose uptake but reduces glycolysis and
impairs glucose utilization as an energy substrate in islets.
Previous studies have demonstrated that under hyperglycemic
conditions, glucose can be shunted toward alternate pathways,
including glycogen synthesis (Malaisse et al., 1993), the pentose
phosphate pathway (PPP; Goehring et al., 2011; Spe´gel et al.,
2013), and/or the hexosamine biosynthesis pathway (HBP; Ka-
neto et al., 2001; Shankar et al., 1998; Tang et al., 2000), which
are all associated with beta cell dysfunction. The observed in-
crease in glucose uptake, together with impaired metabolism,
suggests that CMPF may induce shunting of glucose through
these alternate pathways. To investigate this, we began by
measuring transcript abundance of key rate-limiting enzymes
regulating these processes. We did not observe differences
in expression of glucose-6-phosphate dehydrogenase (G6PD;
Zhang et al., 2010), gluconolactonase (Rgn), or glutamine fruc-
tose-6-phosphate amidotransferase (Gfpt1) (Figure S2E; KanetoReports 14, 2889–2900, March 29, 2016 ª2016 The Authors 2891
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Figure 2. Elevated CMPF Impairs GSIS and Potentiates the Development of Diabetes in Rodent Models
(A–D) Fasting plasma glucose and insulin levels were checked in (A and B) DIO and (C and D) Ob/Ob mouse models, respectively.
(E–H) GTT was performed and corresponding insulin secretion was checked during i.p. GTT on (E and G) DIO and (F and H) Ob/Ob mouse models, respectively.
Area under curve (AUC) inset for (E)–(H): n = 5–8 for GTT and n = 20–32 for others within each group.
(I–L) GSIS and total insulin content was examined in islets isolated from (I and K) DIO and (J and L) Ob/Ob mouse models, respectively.
(M and N) Quantitative analysis of insulin-positive area on pancreatic sections with insulin staining from (M) DIO and (N) Ob/Ob mouse models, respectively.
n = 6–11.
Values are mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2.et al., 2001). To evaluate functionality of these pathways, we
measured G6PDH activity, the rate-limiting enzyme for the PPP,
and O-linked protein glycosylation, a read out of the HBP. There
was no difference in G6PDH activity in CMPF-treated islets
compared to controls (Figure 4D). We observed a reduction in2892 Cell Reports 14, 2889–2900, March 29, 2016 ª2016 The Authortotal O-linked protein glycosylation in islets from Ob/Ob-CMPF
mice compared to controls, suggesting decreased flux through
the HBP (Figure 4E). Overall, these findings suggest that
CMPF does not shunt excess glucose through regulated path-
ways. Consistent with this, we observed an increase in totals
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Figure 3. CMPF Treatment Impairs Glucose
Metabolism by Metabolic Remodeling
(A and C) Glucose-induced hyperpolarization of
the MMP was compared among islets isolated
from the (A) DIO and (C) Ob/Ob mouse models.
(B and D) Palmitic acid-induced hyperpolarization
of the MMP was compared among islets isolated
from (B) DIO and (D) Ob/Ob mouse models. MMP
changes (Dc) inset for (A)–(D).
(E and F) Seahorse-based metabolic flux analysis
using the OCR as an output to evaluate energy
substrate utilization on islets isolated from DIO
mouse models upon loading of (E) 20 mM glucose
and (F) 200 mM palmitic acid.
(G and H) Representative trace from a Seahorse
experiment performed on human islets with addi-
tional loading of (G) 20mMglucose and (H) 200 mM
palmitic acid.
n = 4–12 for animal work and n = 3–4 for human
islet work. Values are mean ± SEM, *p < 0.05, **p <
0.01, ***p < 0.001. RFU, relative fluorescence unit;
AUC, area under curve.glycoprotein content in the islets of CMPF-treated mice com-
pared to controls (Figure 4F), likely due to aberrant protein glyca-
tion. Consistent with an increase in advanced glycation end-
product (AGE) formation (Coughlan et al., 2011), as well as
increased rates of fatty acid oxidation, islets isolated from
both DIO-CMPF and Ob/Ob-CMPF mice exhibited significantly
increased levels of reactive oxygen species (ROS) compared to
controls (Figure 4G). This was not associated with the induction
of islet apoptosis, as quantified by cleaved caspase-3/7 activity
in islets ex vivo (Figure 4H). Thus, CMPF increases beta-oxidation
and decreases glucose metabolism, increasing the formation of
AGEs and ROS, to induce beta cell dysfunction.
CMPF Treatment Impairs Insulin Granule Maturation
Despite impaired beta cell glucose sensitivity and reduced GSIS
in CMPF-treated mice, we observed no reduction in total insulin
content compared to controls (Figures 2K–2N). To more closely
examine the dynamics of insulin biosynthesis and storage with
CMPF treatment, we used transmission electron microscopyCell Reports 14, 2889–2900(TEM). Islets from DIO-control mice ex-
hibited characteristics of early beta cell
dysfunction, including dilated ER (indica-
tive of ER stress), hypertrophic mitochon-
dria, and diminished insulin crystallization
within granules (Figure 5A). This mor-
phology was also observed in the islets
of Ob/Ob-control mice (Figure 5B). Unex-
pectedly, the islets from CMPF-treated
mice contained fewer typical insulin gran-
ules, characterized by a white halo sur-
rounding a dense black core, than either
control (Figures 5A and 5B). Observed
granules included a large number of
membrane-bound structures with ho-
mogenous content, not typical of mature
secretory granules (called immature gran-ules). The number of these structures was significantly increased
with CMPF treatment relative to the number of typical insulin
granules, particularly in the Ob/Ob model (Figures 5C and 5D).
Given the size and orientation of the atypical granules, particu-
larly their close relationship to the Golgi and plasma membrane,
we predict that they may be misprocessed or immature insulin
granules (Figure 5B, indicated by an asterisk). To determine
whether this is the case, we performed immunogold electron mi-
croscopy (immunogold-EM) with antibody staining against insu-
lin in islets from the Ob/Ob-control and Ob/Ob-CMPF mice. We
found that all membrane-bound granule-like structures in islets
from both mice contained insulin (Figure 5F). Given that the anti-
bodies used for immunogold-EM and quantification of total insu-
lin content are unable to distinguish between proinsulin and
mature insulin, we finally quantified the amount of total proinsulin
within the islets of CMPF-treated mice compared to controls.
Consistent with the atypical granules being immature or contain-
ing misprocessed insulin, islets from CMPF-treated mice con-
tained nearly twice asmuch proinsulin as did controls (Figure 5E)., March 29, 2016 ª2016 The Authors 2893
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Figure 4. CMPF Treatment Reduces Glycolysis and Increases AGEs and Oxidative Stress
(A) Seahorse-based metabolic flux analysis using the ECAR as a readout to evaluate the glycolytic rate in islets isolated from DIO mouse models (n = 4–8).
(B–D) 14C-2-deoxyglucose uptake (B) and enzymatic assays evaluating the activity of PDH (C) and G6PDH (D) performed on the primary mouse islet treated with
or without 200 mM CMPF overnight. n = 3–4.
(E) Representative image and quantitative analysis of western blot analyzing O-linked glycosylation level in islets isolated from the Ob/Ob mouse model.
(F) Representative gel image and quantitative analysis of total glycosylated protein staining in islets isolated from the Ob/Ob mouse model.
(G) Representative images and quantitative analysis of ROSmeasurements taken with PTI fluorescencemicroscopy in islets isolated fromDIO andOb/Obmouse
models.
(H) Caspase-3/7 activity measured in islets isolated from the DIO mouse model. n = 4–15.
Values are mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001. RFU, relative fluorescence unit; RLU, relative luminescence unit; O-GlcNAc, O-linked N-acetyl-
glucosamine; LG, low glucose (2 mM); HG, high glucose (20 mM); AUC, area under curve. See also Figure S2.
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Figure 5. CMPF Treatment Impairs Insulin Granule Maturation
(A and B) Representative TEM images of islets isolated from (A) DIO and (B) Ob/Ob mouse models. Arrows and asterisks indicate the immature insulin granules.
(C and D) Quantitative analysis of the relative distribution of dense core versus immature insulin granules within beta cells from (C) DIO and (D) Ob/Ob mouse
models.
(E) Proinsulin content measured in islets isolated from the DIO mouse model.
(F) Representative images of immunogold-EM insulin staining. Arrows indicate insulin-positive staining. n = 3 for TEM and n = 2 for immunogold-EM. n = 10–23 for
proinsulin content.
Values are mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001.Thus, an increase in proinsulin due to impairment of granule
maturation is likely responsible for the increased insulin content
within islets.
Misprocessed or immature proinsulin-containing granules are
characteristic of diabetes progression in humans based onCellnumerous examinations of islets isolated from individuals with
T2D postmortem (Masini et al., 2012; Sempoux et al., 2001).
Furthermore, patients with T2D typically exhibit an increased
proinsulin-to-insulin ratio, which has been suggested to be
involved in impaired insulin signaling in diabetes (Grill et al.,Reports 14, 2889–2900, March 29, 2016 ª2016 The Authors 2895
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Figure 6. CMPF Treatment Increases Proin-
sulin
(A and B) Fasting (A) and fed (B) circulating levels of
proinsulin were analyzed in the DIO mouse model.
(C–E) qPCR analysis comparing gene expression
levels of (C) genes involved in regulating oxidative
and ER stress and mitochondrial oxidative ca-
pacity and (E) genes regulating insulin biosynthesis
in islets isolated from the DIO mouse model. (D)
Representative image and quantitative analysis of
western blot, comparing the LC3BI and LC3BII
protein expression levels in islets isolated from the
DIO mouse model. n = 4–10.
Values are mean ± SEM, *p < 0.05. See also Fig-
ure S2.2002). To examine the underlying cause of the increased number
of immature granules, we began by investigating markers of
impaired protein sorting in the granule maturation process.
Despite significantly increased proinsulin in islets of CMPF-
treatedmice, circulating proinsulin was not significantly changed
between DIO-CMPF mice and DIO-controls in the fasting state,
suggesting the immature granules are not part of the constitutive
pathway of secretion (Figure 6A). However, levels of circulating
proinsulin were significantly increased in the fed state, indicating
these immature granules are capable of secretion (Figure 6B).
Together, these indicate that the defect may not lie in granule
sorting or exocytosis. Immature granules may also accumulate
due to differences in granule degradation (Uchizono et al.,
2007). However, markers of lysosomal activity, the degradation
machinery for misprocessed granules, including Cox2 and
LC3, were not significantly altered in islets from DIO-CMPF
mice compared to controls (Figures 6C and 6D). Furthermore,
there is no indication of elevated ER stress or activation of the
unfolded protein response that would indicate aggregation of
mis-folded insulin within the ER (Chop and Xbp1 expression), a
process that would also signal increased protein degradation
(Figure 6C). Finally, we did not observe any differences in the
transcript levels of the proteolytic genes responsible for insulin
cleavage, including Pc1/2 or CpE (Figure 6E). In conclusion,
the insulin biosynthetic pathway appears to be intact in islets2896 Cell Reports 14, 2889–2900, March 29, 2016 ª2016 The Authorsfrom CMPF-treated mice with DIO or on
an Ob/Ob background. Increased gener-
ation of immature insulin granules may
therefore be attributed to increased levels
of protein glycation, which is known to
alter protein aggregation (Hull et al.,
2004) and could therefore affect protein
sorting and folding within granules.
DISCUSSION
The ultimate cause of T2D is a failure of
the pancreatic beta cells to compensate
for increased demands associated with
insulin resistance. The pathological pro-
gression to diabetes is characterized
by increases in beta cell mass, insulinbiosynthesis, and insulin secretion in the compensatory period,
followed by a decline in function and mass, ultimately resulting
in overt diabetes (Weir and Bonner-Weir, 2004). This decline in
beta cell function has been largely attributed to glucolipotoxicity,
a combination of hyperglycemia and hyperlipidemia acting on
the beta cell to increase ROS production and ER stress and ulti-
mately to induce apoptosis (Poitout et al., 2010; Weir et al.,
2009). However, glucolipotoxic conditions are not prevalent in
the early stages of diabetes progression or even in the predia-
betic period, when there are only mild changes in glucose toler-
ance and circulating free fatty acid levels (Bansal, 2015). In
addition, in acute onset forms of T2D, such as gestational dia-
betes, a model of chronic deterioration in beta cell function
does not match the clinical evolution of the disease.
In thepresent study,weexamined theShanghaiDiabetesStudy
II (SHDS II) prospective cohort (Bao et al., 2010) for changes in
plasma CMPF levels as patients were diagnosed with diabetes
or prediabetes. We found that subjects who had rapid, large in-
creases in plasma CMPF levels during the 4–5 year follow-up
were at a significantly greater risk of developing overt diabetes
in that short period. The levels of CMPF we detect in diabetics in
the present population are comparable to our previous findings
in gestational diabetesmellitus (GDM) and type 2 diabetic popula-
tions thatwere primarilyCaucasian, suggesting this trendmaynot
be specific to anAsian population (Prentice et al., 2014). Basedon
our previous study into the effect of CMPF on impairing beta cell
function (Prentice et al., 2014), we examined whether this dra-
matic increase in CMPF contributes to diabetes progression
through promoting beta cell dysfunction in islets that are in a
compensatory state. We used two models of diabetes develop-
ment (DIO and Ob/Ob), and treatment with CMPF in both models
produced a rapid decline in beta cell function, includingworsened
glucose tolerance, impaired GSIS both in vivo and in vitro,
elevated ROS, and defective insulin processing in the absence
of apoptosis, consistent with our previous observations in a lean
model (Prentice et al., 2014). This decline in beta cell function
was primarily associated with increased beta-oxidation and with
impaired glucose metabolism, resulting in increased protein gly-
cation, ROS, and insulin granulemisprocessing ormaturation, re-
sulting in turn in aberrant proinsulin accumulation. Many of these
effects may be due to the activation of a feedback compensatory
mechanism, resulting in increased glucose uptake in response to
reduced glycolysis and glucose metabolism after CMPF treat-
ment. We attribute the differences in the islet phenotype between
the lean and the obesemodels to obese islets having compensa-
tory mechanisms in place to accommodate for CMPF’s detri-
mental effect. Thus, CMPF has similar effects in both models,
though themechanismof action likely varies based on the pheno-
type of the islet when exposed to CMPF.
Normal pancreatic beta cell function is dependent on appro-
priate insulin cycling, including adequate insulin biosynthesis,
appropriate insulin sorting, and crystallization, as well as insulin
degradation to maintain a readily releasable pool (Uchizono
et al., 2007). As newly formed secretory granules are formed
from the trans-Golgi network, the budding structures contain
various secretory proteins, including proinsulin and lysosomal
proteins (Hou et al., 2009). As granules mature, sorting occurs
and granules divide to remove non-proinsulin proteins into the
lysosomes or the constitutive secretory pathway, leaving proin-
sulin to be cleaved into mature insulin and stored in releasable
insulin pools. Previous work has demonstrated that this matura-
tion process is perturbed in IGT and diabetes states in human
patients, resulting in enhanced proinsulin accumulation and
release (Grill et al., 2002; Sempoux et al., 2001). In the islets of
DIO-CMPF and Ob/Ob-CMPF mice, we observe a profound
accumulation of immature granules and an abundance of proin-
sulin content. These granules are capable of exocytosis, and
mice exhibit a significant elevation in circulating proinsulin in
the fed state compared to controls, similar to the human condi-
tion. We hypothesize that CMPF is altering the course of granule
maturation in part through impairment of carbohydrate utiliza-
tion. In the absence of glucose metabolism with CMPF treat-
ment, glucose accumulates within the cell, resulting in abnormal
formation of AGEs. In the beta cell, increased AGEs may be
associated with aberrant insulin cross-linking, preventing appro-
priate folding and cleavage, to result in increased accumulation
of immature insulin granules (Singh et al., 2001; Vitek et al.,
1994). Future experiments are warranted to extend the under-
standing of the role AGEs play in the context of CMPF and islet
function. Furthermore, induction of oxidative stress associated
with AGE accumulation can act to impair insulin biosynthesis.
ROS reduces Akt activation, resulting in diminished activity of
key beta cell transcription factors PDX1 and MAFA andCellenhanced nuclear translocation of FOXO1, decreasing insulin
transcription and processing (Kawamori et al., 2003). This is
consistent with what was previously observed with CMPF treat-
ment in chow-fed mice (Prentice et al., 2014). Altogether, altered
insulin granule maturation in islets from CMPF-treated mice is
likely caused by alterations to glucose utilization.
The progression from normal glucose tolerance to prediabetes
occurs according to a fairly predictable series of events,
including the induction of insulin resistance, enhanced insulin
output under both basal and glucose-stimulated conditions,
and gradual loss of first-phase insulin secretion, resulting in the
prediabetic state. This prediabetic status with mild alterations
in glucose tolerance can be maintained for years with only min-
imal impact on overall heath. The risk of transition from prediabe-
tes to overt diabetes is about 10% annually, and when this oc-
curs, the evolution is extremely rapid, with fasting blood
glucose levels changing from 7–8 to 16–20 mmol/l within weeks
(Weir and Bonner-Weir, 2004). This development is not associ-
ated with sudden changes in BMI or insulin resistance but is
instead due to a tipping point in beta cell function with complete
failure of compensation. Many argue that this tipping point is
simply due to exhaustion of the beta cell following chronic expo-
sure to glucolipotoxic conditions or ER or oxidative stress. How-
ever, this model is not consistent with acute forms of diabetes,
such as gestational diabetes that occurs only weeks following in-
duction of insulin resistance. Therefore, some independent fac-
tor may be the causal agent underlying this acceleration to
beta cell failure. Our studies in a human population suggest
that a rapid elevation in CMPF may cause this tipping point in
beta cell dysfunction. The rapid elevation of CMPF in rodent
models of diabetes progression accelerates diabetes develop-
ment and produces a beta cell phenotype that closely resembles
the human condition, including reduced glucose sensitivity (Mari
et al., 2010), impaired insulin secretion (Cheng et al., 2013),
elevation in proinsulin content and secretion (Grill et al., 2002;
Sempoux et al., 2001), and ROS formation (Syed et al., 2011).
Thus, elevated circulating CMPF may be a major risk factor for
the development of beta cell failure and contribute to accelerate
the progression of diabetes.EXPERIMENTAL PROCEDURES
Study Population and CMPF Quantification
Fasting plasma sampleswere obtained from theSHDS II cohort of patients rep-
resentingacross-sectional population fromsix regions inShanghai, China (Bao
et al., 2010). Detailed information can be found in Supplemental Information.
Logistic Regression Analysis
Samples with missing a baseline, an outcome, or both values for CMPF were
removed, and the data were log2 transformed. To assess the predictive power
of the change in CMPF between the baseline and the outcome measurements
on the progression to an overt diabetic state, the data were subjected to exact
conditional logistic regression analysis using the clogit function (survival pack-
age from CRAN) in R 3.1.3. Patients who developed diabetes by the follow-up
time point (starting from a NGT or prediabetic state) were compared to sub-
jects who maintained their NGT or prediabetes diagnosis over the course of
the study. Values were treated as both continuous and categorical (split
by quartile of CMPF change) and were stratified by baseline age (binned:
<35, 35–49, 50–64, or >65 years), sex (male or female), BMI (binned: <18.5,
18.5–25, 25–30, or 30–40 kg/m2), and outcome glomerular filtration rateReports 14, 2889–2900, March 29, 2016 ª2016 The Authors 2897
(binned: <90 or >90 ml/min, as calculated by the modification of diet in renal
disease formula). In addition, to assess the relationship between CMPF levels
and additional clinical parameters, individual Spearman correlations were per-
formed between these values in R 3.1.3. Variables found to be significantly
associated with CMPF levels were further assessed, together in a linear model
using the glm function.
Animal Models
All animals were housed in an environmentally controlled facility on a standard
12 hr light/dark cycle with free access to food and water. Seven-week-old
male mice were purchased from Charles River Laboratories (CD1 mice) or
Jackson Laboratory (Ob/Ob mice) and allowed to acclimate for 1 week before
the study. CD1 mice were placed on a HFD with 60% kcal from fat (D12492,
Research Diets) or a matched sucrose chow diet with 10% kcal from fat
(D12450J, Research Diets) for 6 weeks. Mice were maintained on their respec-
tive diets while injected intraperitoneally once daily for 2 weeks with 6 mg/kg
CMPF or vehicle (ethanol; Prentice et al., 2014). CMPF (Cayman Chemical)
was prepared by dissolving in 70% ethanol to a stock concentration of
100 mM and diluted in sterile saline for injection. Ob/ob mice were maintained
on a standard chowdiet (Teklad diet 2018, Harlan Laboratories) throughout the
2 weeks of intraperitoneal (i.p.) injection with 6 mg/kg CMPF or vehicle. Mice
were monitored for body weight weekly.
Glucose Tolerance Tests
At the end of the injection period, i.p. GTTs were performed on mice fasted for
14 hr overnight (Allister et al., 2013). The detailed procedure can be found in
Supplemental Information.
Tissue and Islet Isolation, Insulin Secretion, Apoptosis, Total
Glycoprotein, and Enzymatic Activity Measurements
Mice were anesthetized using isofluorane. Total blood volume was collected
from the chest cavity following removal of the heart. Tissues were collected
and flash frozen in liquid nitrogen for future analysis or fixed in a 4% formalde-
hyde solution for histology. The detailed procedure can be found in Supple-
mental Information. Cleaved caspase-3/7 assay was performed according
to manufacturers’ instructions using 30 islets (G8091, Promega). Total glyco-
protein levels were measured by the Pierce Glycoprotein Staining Kit (catalog
No. 24562, Thermo Fisher Scientific) in polyacrylamide gels according to man-
ufacturers’ instructions. Enzymatic activity assays (catalog No. MAK015,
Sigma, and catalog No. ab109902, Abcam) were used to measure PDH and
G6PDH activity, respectively, according to manufacturers’ instructions.
Histology
Pancreata were fixed in 40% formaldehyde immediately following dissection.
Tissue processing and immunostaining were performed as described previ-
ously (Luu et al., 2013). Images of each section were acquired using Aperio Im-
ageScope at 20x magnification. Quantification of staining was calculated by
using positive pixel count analysis (Aperio ImageScope).
Mitochondrial Membrane Potential
Islets isolated frommicewere loadedwith rhodamine 123 (25 mg/ml) in imaging
buffer without glucose for 10 min. Islets were washed and placed in imaging
chambers containing imaging buffer with no glucose. Images were taken at
10 s intervals at ex:511 nm by an Olympus IX70 inverted epi-fluorescence mi-
croscope in combination with an Ultrapix camera and a computer with Photon
Technology International (PTI) imaging software, as previously described.
Glucose was added to a final concentration of 20 mM to observe the corre-
spondent change of MMP in cells. Alternately, palmitate conjugated to fatty
acid-free BSA was added to a final concentration of 400 mM. Then, 5 mM
NaN3 was added to fully depolarize the MMP (Diao et al., 2008).
Reactive Oxygen Species
The level of H2O2 was determined using 2
0,70-dichlorodihydro-fluorescein di-
acetate (CM-H2-DCFDA; Invitrogen), as previously described (Robson-Douc-
ette et al., 2011). Briefly, isolated islets were loaded with DCFDA for 25 min in
2 mM glucose imaging buffer at 37C. Islets were washed and imaged once at
excitation (ex):475 nm for 20 ms.2898 Cell Reports 14, 2889–2900, March 29, 2016 ª2016 The AuthorHuman Islets and Energy Substrate Utilization Measurements
Human islets from review board-approved healthy donors were provided by
the IsletCore and the Clinical Islet Laboratory (University of Alberta). Islets
were picked into low-glucose DMEM media (Gibco, Catalog No. 11885-084)
with 10% fetal bovine serum, 1% penicillin/streptomyosin, and 1% L-gluta-
mine and were treated with either control, 200 mMCMPF, or 400 mM palmitate
for 24 hr (Prentice et al., 2014). Then, 70 islets were picked into each well of
XF24 islet plates (Seahorse) and secured with a mesh cover, as previously
described (Wikstrom et al., 2012). Cells were incubated in 2 mM glucose
Kreb’s Ring buffer (KRB) without bicarbonate for 1 hr before being loaded
into the XF24 machine. OCR and ECAR were measured at 2 mM glucose, fol-
lowed by either 20 mM glucose or 200 mM palmitate to measure substrate uti-
lization and glycolytic rate, respectively. All islets were then treated with 5 mM
oligomycin, 5 mM FCCP, 5 mM rotenone, and 5 mM antimycin A. Raw traces
were normalized to basal respiration at 2 mM glucose. Glucose uptake was
measured by 2-[14C(U)]-deoxy-D-glucose (NEC720A, PerkinElmer); the
detailed procedure can be found in Supplemental Information.
TEM and Immunogold-EM
Detailed procedures can be found in Supplemental Information.
Gene Expression
The detailed procedure can be found in Supplemental Information.
Western Blotting
The detailed procedure can be found in Supplemental Information.
Statistics
Statistical significance was assessed using either the Student’s t test or one-
way or two-way ANOVA for repeated measures, followed by a Bonferroni,
Dunnett, and Tukey post-test comparison where required. p < 0.05 was
considered significant. All data are mean ± SEM unless otherwise specified.
Study Approval
All animal experiments were approved by the Animal Care Committee at the
University of Toronto, and animals were handled according to the Canadian
Council of Animal Care guidelines. All human studies were approved by a
Shanghai local ethics committee, and written informed consent was received
from participants before inclusion in the study (Bao et al., 2010).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and six tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.02.079.
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